Amalgamated Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,763
| Closed | -$8K | – | 2988 |
|
|
2024
Q4 | $8K | Hold |
2,763
| – | – | ﹤0.01% | 2576 |
|
|
2024
Q3 | $14K | Hold |
2,763
| – | – | ﹤0.01% | 2305 |
|
|
2024
Q2 | $7K | Hold |
2,763
| – | – | ﹤0.01% | 2655 |
|
|
2024
Q1 | $14K | Sell |
2,763
-8,998
| -77% | -$53.3K | ﹤0.01% | 2303 |
|
|
2023
Q4 | $103K | Sell |
11,761
-822
| -7% | -$6.74K | ﹤0.01% | 1991 |
|
|
2023
Q3 | $144K | Hold |
12,583
| – | – | ﹤0.01% | 1892 |
|
|
2023
Q2 | $318K | Buy |
12,583
+1,171
| +10% | +$36.5K | ﹤0.01% | 1649 |
|
|
2023
Q1 | $368K | Sell |
11,412
-1,934
| -14% | -$60.3K | ﹤0.01% | 1557 |
|
|
2022
Q4 | $246K | Buy |
13,346
+1,739
| +15% | +$39.8K | ﹤0.01% | 1777 |
|
|
2022
Q3 | $313K | Buy |
11,607
+555
| +5% | +$11.3K | ﹤0.01% | 1648 |
|
|
2022
Q2 | $153K | Sell |
11,052
-376
| -3% | -$5.79K | ﹤0.01% | 1987 |
|
|
2022
Q1 | $223K | Sell |
11,428
-926
| -7% | -$14K | ﹤0.01% | 1901 |
|
|
2021
Q4 | $202K | Sell |
12,354
-182
| -1% | -$3.03K | ﹤0.01% | 1975 |
|
|
2021
Q3 | $349K | Sell |
12,536
-719
| -5% | -$20.5K | ﹤0.01% | 1775 |
|
|
2021
Q2 | $393K | Buy |
13,255
+5,135
| +63% | +$148K | ﹤0.01% | 1767 |
|
|
2021
Q1 | $227K | Sell |
8,120
-695
| -8% | -$19.2K | 0.01% | 1417 |
|
|
2020
Q4 | $250K | Buy |
8,815
+39
| +0.4% | +$1.01K | 0.01% | 1327 |
|
|
2020
Q3 | $221K | Buy |
+8,776
| New | +$230K | 0.01% | 1276 |
|
Other funds holding RVNC
Amalgamated Bank's RVNC Position: Q1 2025 in Review
Amalgamated Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,763 shares — an estimated $8K sold.
Amalgamated Bank first reported a position in RVNC in Q3 2020 and held it in 18 quarters. The position peaked at $393K in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Amalgamated Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Amalgamated Bank sold 2,763 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $8K.
- Amalgamated Bank first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 18 quarters.
- Amalgamated Bank's Revance Therapeutics, Inc. position peaked at $393K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Amalgamated Bank's 13F filing for Q1 2025, filed 25 Apr 2025.